Information on the new regulations for the post-market surveillance of medical devices which come into effect on 16 June 2025.
Similar Posts
Hepatitis B vaccines for babies
All babies in the UK get the hepatitis B vaccine. It has a well-established safety record and ensures long-term protection against the virus.
Clinical trials for medicines: apply for approval in the UK
How to apply for a clinical trial from 28 April 2026, including eligibility, phases, model IMPDs, costs and how to make changes to your application.
Don’t let the heatwave affect your medicines: Three important tips from the MHRA
Essential advice on protecting your medicines during extreme heat and staying safe this summer.
Rybelsus ® (semaglutide tablets): transition to new formulation and risk of medication error
There is a risk of patient harm arising through medication error during a transition period where the original and new formulation of Rybelsus ® tablets, with different stated mg dose but similar bioavailability, will both be available on the market.
Clinical trials for medicines: apply for authorisation in the UK
How to apply for a clinical trial including eligibility, phases, model IMPDs, costs and how to make changes to your application.
Class 4 Medicines Defect Notification: Dulcolax Adult 5 mg Gastro-resistant Tablets, Opella Healthcare UK, EL(25)A/26
Opella Healthcare UK LTD has informed the MHRA that there is an error on the artwork for the outer carton of Dulcolax Adult 5mg GR Tablets (packsize 20 count). The dose instruction incorrectly states for use in 12 years and older. These general sale packs are intended for use only in adult patients (18 years and over).